These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27018262)

  • 1. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.
    Dubbelman AC; Nijenhuis CM; Jansen RS; Rosing H; Mizuo H; Kawaguchi S; Critchley D; Shumaker R; Schellens JH; Beijnen JH
    Invest New Drugs; 2016 Jun; 34(3):300-18. PubMed ID: 27018262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
    Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
    Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey.
    Inoue K; Asai N; Mizuo H; Fukuda K; Kusano K; Yoshimura T
    Drug Metab Dispos; 2012 Apr; 40(4):662-70. PubMed ID: 22207053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
    Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
    J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
    Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
    Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase.
    Inoue K; Mizuo H; Kawaguchi S; Fukuda K; Kusano K; Yoshimura T
    Drug Metab Dispos; 2014 Aug; 42(8):1326-33. PubMed ID: 24914245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
    Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
    Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
    Hussein Z; Mizuo H; Hayato S; Namiki M; Shumaker R
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):903-914. PubMed ID: 28236116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.
    Brunner V; Maynadier B; Chen L; Roques L; Hude I; Séguier S; Barthe L; Hermann P
    Drug Des Devel Ther; 2015; 9():3199-215. PubMed ID: 26150694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine.
    Dubbelman AC; Jansen RS; Rosing H; Darwish M; Hellriegel E; Robertson P; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Jul; 40(7):1297-307. PubMed ID: 22492615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion and metabolism of recainam, a new anti-arrhythmic drug, in laboratory animals and humans.
    Scatina JA; Wells DS; Kimmel HB; Kemper CJ; Sisenwine SF
    Drug Metab Dispos; 1990; 18(5):746-52. PubMed ID: 1981731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
    Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
    Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.